Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans |
| |
| Authors: | Paul S Aisen Ronald C Petersen Michael C Donohue Anthony Gamst Rema Raman Ronald G Thomas Sarah Walter John Q Trojanowski Leslie M Shaw Laurel A Beckett Clifford R Jack William Jagust Arthur W Toga Andrew J Saykin John C Morris Robert C Green Michael W Weiner |
| |
| Institution: | 2. Department of Neurology, The First People''s Hospital of Hangzhou, Nanjing Medical University, Hangzhou, Zhejiang 310006, China;3. Department of Neurology, Jinling Hospital, Second Military Medical University, Nanjing, Jiangsu 210002, China;4. Department of Neurology, Jinling Hospital, Southern Medical University, Nanjing, Jiangsu 210002, China;6. Department of Neurology, Jinling Hospital, Nanjing Medical University, Nanjing, Jiangsu 210002, China;5. Department of Neurology, Affiliated Hospital 1, Henan University of Science & Technology, Luoyang 471000, China;1. Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, 69120 Heidelberg, Germany;2. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany;3. Institute of Cancer Epidemiology, University of Lübeck, Lübeck, Germany;4. Cancer Registry of Rhineland-Palatinate, Institute for Medical Biostatistics, Epidemiology and Informatics, University Medical Center, Johannes Gutenberg, Germany;5. Saarland Cancer Registry, Saarbrüken, Germany;6. Bayern Cancer Registry, Munich, Germany;7. Cancer Registry of Bremen, Leibniz-Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany;8. Center for Primary Health Care Research, Lund University, Malmö, Sweden;9. Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, CA 94305-5705, USA;10. Division of Preventive Oncology, German Cancer Research Center, Heidelberg, Germany;11. German Cancer Consortium (DKTK), Heidelberg, Germany |
| |
| Abstract: | The Clinical Core of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has provided clinical, operational, and data management support to ADNI since its inception. This article reviews the activities and accomplishments of the core in support of ADNI aims. These include the enrollment and follow-up of more than 800 subjects in the three original cohorts: healthy controls, amnestic mild cognitive impairment (now referred to as late MCI, or LMCI), and mild Alzheimer's disease (AD) in the first phase of ADNI (ADNI 1), with baseline longitudinal, clinical, and cognitive assessments. These data, when combined with genetic, neuroimaging, and cerebrospinal fluid measures, have provided important insights into the neurobiology of the AD spectrum. Furthermore, these data have facilitated the development of novel clinical trial designs. ADNI has recently been extended with funding from an NIH Grand Opportunities (GO) award, and the new ADNI GO phase has been launched; this includes the enrollment of a new cohort, called early MCI, with milder episodic memory impairment than the LMCI group. An application for a further 5 years of ADNI funding (ADNI 2) was recently submitted. This funding would support ongoing follow-up of the original ADNI 1 and ADNI GO cohorts, as well as additional recruitment into all categories. The resulting data would provide valuable data on the earliest stages of AD, and support the development of interventions in these critically important populations. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
